Overview

• Under the terms of the agreement, Sanofi will pay $1.15 billion upfront and could make up to $450 million in milestone payments for all of Vicebio’s share capital.
• Vicebio’s lead candidate, VXB-241, is a bivalent vaccine targeting RSV and hMPV currently in a Phase 1 trial in older adults.
• The deal also brings VXB-251, a preclinical trivalent vaccine candidate against RSV, hMPV and parainfluenza virus type 3, into Sanofi’s pipeline.
• Vicebio’s licensed Molecular Clamp technology stabilizes viral proteins in their native shape to enable fully liquid vaccines storable at standard refrigeration temperatures (2–8 °C).
• The transaction is subject to customary closing conditions and regulatory approvals and is expected to complete in the fourth quarter of 2025 without affecting Sanofi’s 2025 financial guidance.